-
1Academic Journal
Authors: Mazurenko, O.P.
Source: EMERGENCY MEDICINE; № 6.101 (2019); 111-115
МЕДИЦИНА НЕОТЛОЖНЫХ СОСТОЯНИЙ; № 6.101 (2019); 111-115
МЕДИЦИНА НЕВІДКЛАДНИХ СТАНІВ; № 6.101 (2019); 111-115Subject Terms: 03 medical and health sciences, 0302 clinical medicine, механическая поддержка кровообращения, устройство механической поддержки левого желудочка с непрерывным потоком, застойная сердечная недостаточность у детей, механічна підтримка кровообігу, пристрій механічної підтримки лівого шлуночка з безперервним потоком, застійна серцева недостатність у дітей, mechanical circulatory support, continuous-flow left ventricular assist device, congestive heart failure in children, 3. Good health
File Description: application/pdf
-
2Academic Journal
Authors: Bentsa, T. M.
Source: Medicine of Ukraine; № 1(237) (2020); 44-47
Лекарства Украины; № 1(237) (2020); 44-47
Ліки України; № 1(237) (2020); 44-47Subject Terms: 2. Zero hunger, nonalcoholic fatty liver disease, cardiovascular disease, atherosclerosis, arterial hypertension, congestive heart failure, cardiac arrhythmias, УДК 616.36-007.1:616.12-008.331]-039, 10. No inequality, неалкогольная жировая болезнь печени, сердечно-сосудистые заболевания, атеросклероз, артериальная гипертензия, застойная сердечная недостаточность, нарушения ритма сердца, неалкогольна жирова хвороба печінки, серцево-судинні захворювання, артеріальна гіпертензія, застійна серцева недостатність, порушення ритму серця, 3. Good health
File Description: application/pdf
-
3Academic Journal
Authors: Oleg, CALENICI, Alexandr, CARAUSH, Anna, MOISEEVA, Maria, COCIU, Ludmila, UNTURA, Mihaela, CARAUSH
Source: Bulletin of the Academy of Sciences of Moldova. Medical Sciences; Vol. 72 No. 1 (2022): Medical Sciences; 123-129 ; Buletinul Academiei de Științe a Moldovei. Științe medicale; Vol. 72 Nr. 1 (2022): Ştiinţe medicale; 123-129 ; Вестник Академии Наук Молдовы. Медицина; Том 72 № 1 (2022): Медицина; 123-129 ; 1857-0011 ; 10.52692/1857-0011.2022.1-72
Subject Terms: Застойная сердечная недостаточность, систолическая функция левого желудочка, диастолическая функция, Insuficiență cardiacă congestivă, funcție sistolică a ventriculului stâng, funcție diastolică, Congestive heart failure, preserved left ventricular systolic function, diastolic function
File Description: application/pdf
Relation: https://bulmed.md/bulmed/article/view/3414/3417; https://bulmed.md/bulmed/article/view/3414
-
4Academic Journal
Diastolic left ventricular dysfunction and heart failure with preserved ejection fraction in elderly
Authors: Calenici, O.S., Carauş, A.P., Caraush, A., Moiseeva, A.N., Cociu, M., Untura, L., Carauş, M., Caraush, M.
Source: Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale 72 (1) 123-129
Subject Terms: funcție diastolică, congestive heart failure, Застойная сердечная недостаточность, диастолическая функция, funcție sistolică a ventriculului stâng, preserved left ventricular systolic function, diastolic function, Insuficiență cardiacă congestivă, систолическая функция левого желудочка
File Description: application/pdf
Access URL: https://ibn.idsi.md/vizualizare_articol/153787
-
5Academic Journal
Authors: R. S. Tarasov, A. V. Protopopov, N. S. Bokhan, O. A. Nagirnyak, I. N. Sizova, V. I. Ganyukov, Р. С. Тарасов, А. В. Протопопов, Н. С. Бохан, О. А. Нагирняк, И. Н. Сизова, В. И. Ганюков
Source: Complex Issues of Cardiovascular Diseases; Том 7, № 3 (2018); 134-139 ; Комплексные проблемы сердечно-сосудистых заболеваний; Том 7, № 3 (2018); 134-139 ; 2587-9537 ; 2306-1278 ; 10.17802/2306-1278-2018-7-3
Subject Terms: Массивный тромбоз левого предсердия, Balloon mitral valvuloplasty, Congestive heart failure, Massive thrombosis of the left atrium, Баллонная митральная вальвулопластика, Застойная сердечная недостаточность
File Description: application/pdf
Relation: https://www.nii-kpssz.com/jour/article/view/460/354; Клинические рекомендации по ведению, диагностике и лечению клапанных пороков сердца. М.: Изд-во НЦССХ им. А. Н. Бакулева РАМН; 2009.; Harb S.C., Griffin B.P. Mitral Valve Disease: a Comprehensive Review. // Curr Cardiol Rep. 2017 Aug; 19(8):73. doi:10.1007/s11886-017-0883-5.; Torii S., Romero M.E., Mori H., Harari E., Kolodgie F.D., Finn A.V., Virmani R. The spectrum of mitral valve pathologies: relevance for surgical and structural interventions. Expert Rev Cardiovasc Ther. 2017 Jul;15(7):525-535. doi:10.1080/14779072.2017.1348230.; Jaber W.A., Prior D.L., Thamilarasan M., Grimm R.A., Thomas J.D., Klein A.L., Asher C.R. Efficacy of anticoagulation in resolving left atrial and left atrial appendage thrombi: a transesophageal echocardiographic study. Am Heart J. 2000;140:150–6. DOI:10.1067/mhj.2000.106648; Bonow R.O., Carabello B., de Leon A.C., Edmunds L.H. Jr, Fedderly B.J., Freed M.D. ACC/AHA guidelines for the management of patients with valvular heart disease: executive summary. A report of the American College of Cardiology/ American Heart Association task force on practice guidelines (committee on management of patients with valvular heart disease). J Heart Valve Dis. 1998 Nov;7(6):672-707.; Одаренко Ю.Н., Рутковская Н.В., Рогулина Н.В., Стаче А.Н., Кокорин С.Г., Каган Е.С. Барбараш Л.С. Анализ 23-летнего опыта использования ксеноаортальных эпоксиобработанных биопротезов в хирургии митральных пороков сердца. исследование факторов реципиента с позиций влияния на развитие кальциевой дегенерации. Комплексные проблемы сердечно-сосудистых заболеваний. 2015;(4):17-25. DOI:10.17802/2306-1278-2015-4-17-25.
-
6Academic Journal
Authors: N. Yu. Karpova, N. S. Chipigina, K. A. Rogov, A. M. Sdvizhkov, M. A. Rashid, J. I. Banova, E. M. Levin, Н. Ю. Карпова, Н. С. Чипигина, К. А. Рогов, А. М. Сдвижков, М. А. Рашид, Ж. И. Банова, Е. М. Левин
Source: The Russian Archives of Internal Medicine; Том 7, № 6 (2017); 474-479 ; Архивъ внутренней медицины; Том 7, № 6 (2017); 474-479 ; 2411-6564 ; 2226-6704 ; 10.20514/2226-6704-2017-7-6
Subject Terms: пожилые, pericardium, mesothelioma, congestive heart failure, pulmonary embolism, elderly, перикард, мезотелиома, застойная сердечная недостаточность, легочная эмболия
File Description: application/pdf
Relation: https://www.medarhive.ru/jour/article/view/724/623; Santos C., Montesinosa J., Castañera E., Sole J.M., Baga R. Primary pericardial mesothelioma. Lung Cancer. 2008; 60: 291–293.; Vogelzang N.J., Rusthoven J.J., Symanowski J., Denham C., Kaukel E., Ruffie P., Gatzemeier U., Boyer M., Emri S., Manegold C., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003; 21: 2636–2644.; Russell Fernandes, Shravan Nosib, Dorothy Thomson, Nick Baniak A rare cause of heart failure with preserved ejection fraction: primary pericardial mesothelioma masquerading as pericardial constriction BMJ Case Rep. 2014; 2014: bcr2013203194.; Papi M., Genestreti G., Tassinari D. et al. Malignant pericardial mesothelioma. Report of two cases, review of the literature and differential diagnosis. Tumori. 2005 May-Jun; 91(3): 276-279.; Karadzic R., Kostic-Banovic L., Antovic A., Celar M., Katic V., Ilic G., Stojanovic J. Primary pericardial mesothelioma presenting as constrictive pericarditis. Arch. Oncol. 2005; 13: 150–152.; Yang G.Z., Li J., Ding H.Y. Localized malignant myxoid anaplastic mesothelioma of the pericardium. J. Clin. Med. Res. 2009; 1: 115–118.; Sardar M.R., Kuntz C., Patel T., et al. Primary pericardial mesothelioma unique case and literature review. Tex. Heart Inst. J. 2012; 39: 261–264.; Patel J., Sheppard M.N. Primary malignant mesothelioma of the pericardium. Cardiovasc. Pathol. 2011; 20: 107–109.; Mensi C., Giacomini S., Sieno C., Consonni D., Riboldi L. Pericardial mesothelioma and asbestos exposure. Int. J. Hyg. Environ. Health. 2011; 214: 276–279.; Åse Nilsson, Torgny Rasmuson Primary Pericardial Mesothelioma: Report of a Patient and Literature Review Case Rep Oncol. 2009 May-Aug; 2(2): 125–132.; Suman S., Schofield P., Large S. Primary pericardial mesothelioma presenting as pericardial constriction: A case report. Heart. 2004; 90: e4. doi:10.1136/heart.90.1.e4; Nambiar C.A., Tareif H.E., Kishore K.U., Ravindran J., Banerjee A.K. Primary pericardial mesothelioma: one-year event-free survival. Am. Heart J. 1992; 124(3): 802–803.; Kaul T.K., Fields B.L., Kahn D.R. Primary malignant pericardial mesothelioma: A case report and review. J. Cardiovasc .Surg (Torino). 1994; 35: 261–267.; Fazekas T., Tiszlavicz L., Ungi I. Primary malignant pericardial mesothelioma Orv. Hetil. 1991 Dec 1; 132(48): 2677-2680.; Daniel C. Lingamfelter, Dominick Cavuoti, and Amy C. Gruszecki Fatal hemopericardial tamponade due to primary pericardial mesothelioma: a case report Diagn Pathol. 2009; 4: 44.; Uspenskiy Vladimir, Lavreshin Alexei, Osadchii Alexei, Gordeev Michael. False aneurysm of ascending aorta due to pericardial mesothelioma Interact. Cardiovasc. Thorac. Surg. 2012 Aug; 15(2): 301–303.; Wenhui Gong, Xiaofeng Ye, Kaihu Shi, and Qiang Zhao. Primary malignant pericardial mesothelioma—a rare cause of superior vena cava thrombosis and constrictive pericarditis. J. Thorac. Dis. 2014 Dec; 6(12): E272–E275.; Butz T., Yeni H., Van Bracht M., Christ M., Plehn G., Machnick S., et al. Massive pericarditis constrictiva calcarea with compression of the right ventricle and consecutive pulmonary embolism. Eur. J. Echocardiogr. 2009; 10(2): 344–346.; Vertun-Baranowska B., Fijalkowska A., Tomkowski W., Filipecki S., Szymanska D. Pulmonary embolism in malignancy of the lung: a retrospective clinical evaluation and pathomorphologic personal material [in Polish]. Pneumonol. Alergol. Pol. 1996; 64(7–8): 392–402.; Gössinger H.D., Siostrzonek P., Zangeneh M., Neuhold A., Herold C., Schmoliner R. et al. Magnetic resonance imaging findings in a patient with pericardial mesothelioma. Am. Heart J. 1988; 115: 1321–1322.; Ohnishi J., Shiotani H., Ueno H., Fujita N., Matsunaga K. Primary pericardial mesothelioma demonstrated by magnetic resonance imaging. Jpn. Circ. J. 1996; 60: 898–900.; Ahmadreza Jodati, Babak Kazemi, Naser Safaei, and Mehrnoush Toufan. A Ball in the Heart: An Interesting Discovery in a Very RareCardiac Tumor. J. Cardiovasc. Thorac. Res. 2013; 5(2): 77–80.; Aga F., Yamamoto Y., Norikane T., Nishiyama Y. A case of primary pericardial mesothelioma detected by 18F-FDG PET/CT. Clin. Nucl. Med. 2012 May; 37(5): 522-523.; Nilsson A., Rasmuson T. Primary pericardial mesothelioma: Report of a patient and literature review. Case Rep. Oncol. 2009; 2: 125–132.; Thomason R., Schlegel W., Lucca M., Cummings S., Lee S. Primary malignant mesothelioma of the pericardium. Case report and literature review. Tex. Heart Inst. J. 1994; 21: 170–174.; Eren N.T., Akar A.R. Primary pericardial mesothelioma. Curr. Treat. Options Oncol. 2002; 3: 369–373.; Elizabeth A. Oczypok, Tim D. Oury, Electron microscopy remains the gold standard for the diagnosis of epithelial malignant mesothelioma: A case study Ultrastruct Pathol. 2015; 39(2): 153–158.; Hollevoet K., Reitsma J.B., Creaney J., Grigoriu B.D., Robinson B.W., Scherpereel A., Cristaudo A., Pass H.I., Nackaerts K., Rodríguez Portal J.A., et al. Serum mesothelin for diagnosing malignant pleural mesothelioma: An individual patient data meta-analysis. J. Clin. Oncol. 2012; 30: 1541–1549.; Takeyuki Kurosawa, Keishi Sugino, Kazutoshi Isobe et al. Primary malignant pericardial mesothelioma with increased serum mesothelin diagnosed by surgical pericardial resection: A case report. Mol. Clin. Oncol. 2016; 5(5): 553–556.; Vigneswaran W.T., Stefanacci P.R. Pericardial mesothelioma. Curr. Treat. Options Oncol. 2000; 1: 299–302.; https://www.medarhive.ru/jour/article/view/724
-
7Academic Journal
Source: Research and Practical Medicine Journal; Том 2, № 4 (2015); 106-114 ; Research'n Practical Medicine Journal; Том 2, № 4 (2015); 106-114 ; 2410-1893 ; 10.17709/2409-2231-2015-4
Subject Terms: застойная сердечная недостаточность, life quality, anthracyclines, trastuzumab, congestive heart failure, качество жизни, антрациклины, трастузумаб
File Description: application/pdf
Relation: https://www.rpmj.ru/rpmj/article/view/109/116; Bardia A., Arieas E. T., Zhang Z., Defilippis A., Tarpinian K., Jeter S., Nguyen A., Henry N. L., Flockhart D. A., Hayes D. F., Hayden J., Storniolo A. M., Armstrong D. K., Davidson N. E., Fetting J., Ouyang P., Wolff A. C., Blumenthal R. S., Ashen M. D., Stearns V. Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer. Breast Cancer Res Treat. 2012; 131 (3): 907–914.; ESMO Guidelines Breast Cancer, 2014.; Perez E. A., Suman V. J., Davidson N. E., Kaufman P. A., Martino S., Dakhil S. R., Ingle J. N., Rodeheffer R. J., Gersh B. J., Jaffe A. S. Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. J Clin Oncol. 2004; 22: 3700–3704.; Michael S. Ewer, Edward T. H. Yeh. Cancer and the Heart, Second Edition, PMPH-USA, 2013.; Barrett-Lee P. J., Dixon J. M., Farrell C., Jones A., Leonard R., Murray N., Palmieri C., Plummer C. J., Stanley A., Verrill M. W. Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. Ann Oncol. 2009; 20: 816–827.; Bryant J., Picot J., Baxter L., Levitt G., Sullivan I., Clegg A. Clinical and cost-effectiveness of cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review. British Journal of cancer. 2007; 96 (2): 226–230.; Jensen B. V., Skovsgaard T., Nielsen S. L. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, longterm observational study of outcome in 120 patients. Ann Oncol. 2002; 13: 699–709.; James L. Speyer, Michael D. Green, Anne Zeleniuch-Jacquotte et al. ICRF‑187 Permits Longer Treatment With Doxorubicin in Women With Breast Cancer. Journal of Clinical Oncology. 1992; 10 (1): 117–127.; Rowinsky E. K., Eisenhauer E. A., Chaudhry V., Arbuck S. G., Donehower R. C. Clinical toxities encountered with paclitaxel (Taxol). Semin Oncol. 1993; 4 (3); 1–15.; Meinardi M. T., Gietema J. A., van der Graaf W. T., van Veldhuisen D. J., Runne M. A., Sluiter W. J., de Vries E. G., Willemse P. B., Mulder N. H., van den Berg M. P., Koops H. S., Sleijfer D. T. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol. 2000; 18 (8): 1725–1732.; Oh J. H., Baum D. D., Pham S. Long-term complications of platinum-based chemotherapy in testicular cancer survivors. Med Oncol. 2007; 24 (2): 175–181.; Du X. L., Xia R., Burau K., Liu C. C. Cardiac risk associated with the receipt of anthracycline and trastuzumab in a large nationwide cohort of older women with breast cancer, 1998–2005. Med Oncol. 2011; 28: 80–90. DOI 10.1007/s12032–010–9717–7.; Slamon D. J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J., Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpressed HER2. N Engl J Med. 2001; 344: 783–792.; Piccart-Gebhart M. J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., Gianni L., Baselga J., Bell R., Jackisch C., Cameron D., Dowsett M., Barrios C. H., Steger G., Huang C. S., Andersson M., Inbar M., Lichinitser M., Láng I., Nitz U., Iwata H., Thomssen C., Lohrisch C., Suter T. M., Rüschoff J., Suto T., Greatorex V., Ward C., Straehle C., McFadden E., Dolci M. S., Gelber R.D; Herceptin Adjuvant (HERA) Trial Study Team. Herceptin adjuvant (HERA) trial study team. Trastuzumab after adjuvant chemotherapy in HER2‑posi- tive breast cancer. N Engl J Med. 2005; 353: 1659–1672.; Romond E. H., Perez E. A., Bryant J., Suman V. J., Geyer C. E. Jr, Davidson N. E., Tan-Chiu E., Martino S., Paik S., Kaufman P. A., Swain S. M., Pisansky T. M., Fehrenbacher L., Kutteh L. A., Vogel V. G., Visscher D. W., Yothers G., Jenkins R. B., Brown A. M., Dakhil S. R., Mamounas E. P., Lingle W. L., Klein P. M., Ingle J. N., Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2‑positive breast cancer. N Engl J Med. 2005; 353: 1673–1684.; Tan-Chiu E., Yothers G., Romond E., Geyer C. E. Jr, Ewer M., Keefe D., Shannon R. P., Swain S. M., Brown A., Fehrenbacher L., Vogel V. G., Seay T. E., Rastogi P., Mamounas E. P., Wolmark N., Bryant J. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2‑over- expressing breast cancer: NSABP B31. J Clin Oncol. 2005; 23: 7811–7819.; Perez E. A., Suman V. J., Davidson N. E., Sledge G. W., Kaufman P. A., Hudis C. A., Martino S., Gralow J. R., Dakhil S. R., Ingle J. N., Winer E. P., Gelmon K. A., Gersh B. J., Jaffe A. S., Rodeheffer R. J. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by Paclitaxel with or without Trastuzumab in the north central cancer treatment group N9831 adjuvant breast cancer trial. J Clin Oncol. 2008; 26: 1231–1238.; Procter M., Suter T. M., de Azambuja E., Dafni U., van Dooren V., Muehlbauer S., Climent M. A., Rechberger E., Liu W. T., Toi M., Coombes R. C., Dodwell D., Pagani O., Madrid J., Hall M., Chen S. C., Focan C., Muschol M., van Veldhuisen D. J., Piccart-Gebhart M. J. Longer-term assessment of trastuzumab-related cardiac adverse events in the Her- ceptin Adjuvant (HERA) trial. J Clin Oncol. 2010; 28: 3422–3428.; Baselga J., Cortés J., Kim S. B., Im S. A., Hegg R., Im Y. H., Roman L., Pedrini J. L., Pienkowski T., Knott A., Clark E., Benyunes M. C., Ross G., Swain S. M.; CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2011; 366 (2): 109–119.; Swain S. M., Kim S. B., Cortés J., Ro J., Semiglazov V., Campone M., Ciruelos E., Ferrero J. M., Schneeweiss A., Knott A., Clark E., Ross G., Benyunes MC, Baselga J. Pertuzumab, trastuzumab, and docetaxel for HER2‑positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013; 14 (6): 461–471. doi:10.1016/S1470–2045 (13)70130‑X.; Wolff A. C., Wang M., Li H., Pins M. R., Pretorius F. J., Rowland K. M., Sparano J. A., Davidson N. E. Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group trial E3198. Breast Cancer Res Treat. 2010; 121: 111–120.; Chia S., Clemons M., Martin L. A., Rodgers A., Gelmon K., Pond G. R., Panasci L. Pegylated liposomal doxorubicin and trastuzumab in HER‑2 overexpressing metastatic breast cancer: a multicenter phase II trial. J Clin Oncol. 2006; 24: 2773–2778.; Andreopoulou E., Gaiotti D., Kim E., Volm M., Oratz R., Freedberg R., Downey A., Vogel C. L., Chia S., Muggia F. Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2‑overexpressing metastatic breast cancer. Clin Breast Cancer. 2007; 7: 690–696.; Stickeler E., Klar M., Watermann D., Geibel A., Földi M., Hasenburg A., Gitsch G. Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial. Breast Cancer Res Treat. 2009; 117 (3): 591–598. doi:10.1007/s10549–008–0306–9.; Christodoulou C., Kostopoulos I., Kalofonos H. P., Lianos E., Bobos M., Briasoulis E., Gogas H., Razis E., Skarlos D. V., Fountzilas G.; Study of the Hellenic Cooperative Oncology Group. Trastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer: phase II study of the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation. Oncology. 2009; 76: 275–285.; O’Brien M. E., Wigler N., Inbar M., Rosso R., Grischke E., Santoro A., Catane R., Kieback D. G., Tomczak P., Ackland S. P., Orlandi F., Mellars L., Alland L., Tendler C.; CAELYX Breast Cancer Study Group. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004; 15 (3): 440–449.; Perez E. A., Koehler M., Byrne J., Preston A. J., Rappold E., Ewer M. S. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clinic Proc. 2008; 83 (6): 679–686.; Pircher M., Mlineritsch B., Fridrik M. A., Dittrich C., Lang A., Petru E., Weltermann A., Thaler J., Hufnagl C., Gampenrieder S. P., Rinnerthaler G., Ressler S., Ulmer H., Greil R. Lapatinib-plus-pegylated liposomal doxorubicin in advanced her2‑positive breast cancer following trastuzumab: a phase ii trial. Anticancer Res. 2015; 35 (1): 517–522.; Yeh ET., Tong A. T., Lenihan D. J., Yusuf S. W., Swafford J., Champion C., Durand J. B., Gibbs H., Zafarmand A. A., Ewer M. S. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation. 2004; 109: 3122–3131.; Felker G. M., Thompson R. E., Hare J. M., Hruban R. H., Clemetson D. E., Howard D. L., Baughman K. L., Kasper E. K. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000; 342: 1077–1084.; Chen M., Colan S., Diller L. Cardiovascular disease: cause of morbidity and mortality in adult survivors of childhood cancers. Circ Res. 2011; 108: 619–628.; Sawyer D., Lenihan D. Managing heart failure in cancer patients. In: Mann D., Felker G. Heart Failure: A Companion to Braunwald’s Heart Disease, 3d ed. Philadelphia, Elsevier. 2016.; Tan-Chiu E., Yothers G., Romond E., Geyer C. E. Jr, Ewer M., Keefe D., Shannon R. P., Swain S. M., Brown A., Fehrenbacher L., Vogel V. G., Seay T. E., Rastogi P., Mamounas E. P., Wolmark N., Bryant J. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2‑overexpressing breast cancer: NSABP B‑31. J Clin Oncol. 2005; 23: 7811–7819.; Swain S., Whaley F., Ewer M. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003; 97: 2869–2879.; Lang R. M., Badano L. P., Mor-Avi V., Afilalo J., Armstrong A., Ernande L., Flachskampf F. A., Foster E., Goldstein S. A., Kuznetsova T., Lancellotti P., Muraru D., Picard M. H., Rietzschel E. R., Rudski L., Spencer K. T., Tsang W., Voigt J. U. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015; 28: 1–39.; Plana J. C., Galderisi M., Barac A., Ewer M. S., Ky B., Scherrer-Crosbie M., Ganame J., Sebag I. A., Agler D. A., Badano L. P., Banchs J., Cardinale D., Carver J., Cerqueira M., DeCara J. M., Edvardsen T., Flamm S. D., Force T., Griffin B. P., Jerusalem G., Liu J. E., Magalhães A., Marwick T., Sanchez L. Y., Sicari R., Villarraga H. R., Lancellotti P. Expert consensus for multimodality imaging evaluation of adult cancer patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014; 27: 911–939.; van Dalen E. C., Caron H. N., Dickinson H. O., Kremer L. C. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev. 2011; 6: CD003917. doi:10.1002/14651858.CD003917.pub4.; Orditura M., Quaglia F., Morgillo F., Martinelli E., Lieto E., De Rosa G., Comunale D., Diadema M. R., Ciardiello F., Catalano G., De Vita F. Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracycline-induced cardiotoxicity (review). Oncology reports. 2004; 12: 549–556.; O’Shaughnessy J. Pegylated Liposomal Doxorubicin in the Treatment of Breast Cancer. Clin Breast Cancer. 2003; 4: 318–328.; O’Brien M. E., Wigler N., Inbar M., Rosso R., Grischke E., Santoro A., Catane R., Kieback D. G., Tomczak P., Ackland S. P., Orlandi F., Mellars L., Alland L., Tendler C.; CAELYX Breast Cancer Study Group. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004; 15: 440–449.; Cardinale D., Colombo A., Sandri M. T., Lamantia G., Colombo N., Civelli M., Martinelli G., Veglia F., Fiorentini C., Cipolla C. M. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006; 114: 2474–2481.; Kalay N., Basar E., Ozdogru I., Er O., Cetinkaya Y., Dogan A., Inanc T., Oguzhan A., Eryol N. K., Topsakal R., Ergin A. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2006; 48: 2258–2262.; Georgakopoulos P., Roussou P., Matsakas E., Karavidas A., Anagnostopoulos N., Marinakis T., Galanopoulos A., Georgiakodis F., Zimeras S., Kyriakidis M., Ahimastos A. Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36‑month follow-up. Am J Hematol. 2010; 85: 894–896.; Cardinale D., Colombo A., Lamantia G., Colombo N., Civelli M., De Giacomi G., Rubino M., Veglia F., Fiorentini C., Cipolla C. M. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010; 55: 213–220.; Lipshultz S. E., Lipsitz S. R., Sallan S. E., Simbre V. C. 2nd, Shaikh S. L., Mone S. M., Gelber R. D., Colan S. D. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol. 2002; 20: 4517–4522.; Tallaj J. A., Franco V., Rayburn B. K., Pinderski L., Benza R. L., Pamboukian S., Foley B., Bourge R. C. Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure. J Heart Lung Transplant. 2005; 24: 2196–2201.; Jensen B., Skovsgaard T., Nielsen S. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol. 2002; 13: 699–709.; https://www.rpmj.ru/rpmj/article/view/109
-
8Academic Journal
Authors: АЛЕКСАНДРОВА А.А., КОЛОС И.П., ДУПИК Н.В., ЛАЗЕБНИК Л.Б.
File Description: text/html
-
9Academic Journal
Authors: Ж. АКИМБАЕВА
Subject Terms: артериальная гипертензия, сахарный диабет 2-го типа, коронарная болезнь сердца, застойная сердечная недостаточность, ампутации нижних конечностей
File Description: text/html
-
10Academic Journal
Subject Terms: рак молочной железы, качество жизни, антрациклины, трастузумаб, застойная сердечная недостаточность
File Description: text/html
-
11Academic Journal
Authors: G. P. Itkin, Г. П. Иткин
Source: Russian Journal of Transplantology and Artificial Organs; Том 16, № 3 (2014); 76-84 ; Вестник трансплантологии и искусственных органов; Том 16, № 3 (2014); 76-84 ; 1995-1191 ; 10.15825/1995-1191-2014-3
Subject Terms: имплантируемый осевой насос, heart transplantation, severe heart failure, mechanical circulation support, assisted circulation, pulsatile and non-pulsatile pumps, implantable axial flow pump, трансплантация сердца, застойная сердечная недостаточность, механическая поддержка кровообращения, вспомогательное кровообращение, пульсирующие и непульсирующие насосы
File Description: application/pdf
Relation: https://journal.transpl.ru/vtio/article/view/450/395; Anderson DW. Blood pump: thechnologies and markets in transformation. Artif. Organs. 2001; 25: 406–441.; http://www.dhzb.ru/statistika.htm.; Muntwyler J, Abetel G, Gruner C, Follath F. One-year mortality among unselected outpatient with heart failure. Eur Heart J. 2002; 23: 1861–1866.; Pennington DG. Mechanical circulation support for acute heart failure. The Annals of Thoracic Surgery. 2001;71: S59–S59.; Spencer FC, Eiseman B, Trinkle JK. Assisted circulation for cardiac failure following intra-cardiac surgery with cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1965; 49: 56–73.; Kirklin K, Naftel D, Kormos R, Stevenson LW, Pagani FD, Miller MA et al. The Fourth INTERMACS annual Report: 4,000 implants and counting. J Heart Lung Transplant. 2012; 31 (2): 117–126.; Kavarana MN, Pessin-Minsley MS, Urtecho J, Catanese KA, Flannery M, Oz MC, Naka Y. Right ventricular dysfunction and organ failure in left ventricular assist device recipients: a continuing problem. Ann Thorac Surg. 2002; 73: 745–750.; Dipla K, Mattiello J, Jeevanandam V, Houser SR, Margulies KB. Myocyte Recovery After Mechanical Circulatory Support in Humans With End-Stage Heart Failure. Circulation. 1998; 97: 2316–2322.; Lenneman AJ, Birks EJ. Treatment Strategies for Myocardial Recovery in Heart. Failure Curr Treat Options Cardio Med. 2014; 287: 1–9.; Kirklin JK, Naftel DC, Kormos RL, Stevenson LW, Pagani, Miller MA, Baldwin JB, Young JB. Fifth INTERMACS annual report: Risk factor analysis from more than 6,000 mechanical circulatory support patients. J Heart Lung Transplant. 2013; 32: 141–156.; Giridharan GA, Lee TJ, Ising M, Sodieski MA, Koenig SC, Gray LA, Slaughter MS. Miniaturization of Mechanical circulatory support systems. Artif Organs. 2012; 36: 731–758.; Klotz S, Meyns B, Simon A, Wittwer T, Rahmanian P, Schlensak C et al. Partial Mechanical Long-Term Support with the CircuLite® Synergy® Pump as Bridge-to- Transplant in Congestive Heart Failure. Thorac Cardiov Surg. 2010; 58, Suppl. 2: S173–S178.; Dunkan BW, Dudzinski DT, Gu L, Mielke N, Noecker AM, Kopscak MW et al. PediPump: Development Status of a New Pediatric Ventricular Assist Device: Update II. ASAIO J. 2006; 52: 581–587.; Hayward CS, Peters WS, Merry AF. Chronic extra-aortic balloon counterpulsation: first-in-human pilot study in end- stage heart failure. J Heart Lung Transplant. 2010; 29: 1427–1432.; Slales VL, McCarthy PM. Understanding the C-pulse device and its potential to treat heart failure. Curr Heart Fail Rep. 2010; 7: 27–34.; Иткин ГП, Шемакин СЮ, Шохина ЕГ, Бурцев ВИ, Аврамов ПВ, Волкова ЕА и др. Результаты экспериментальных исследований на телятах первого отечественного имплантируемого осевого насоса. Вестник трансплантологии и искусственных органов. 2013; 3: 49–58. Itkin GP, Shemakin SYu, Shokhina EG, Burtsev VI, Avramov PV, Volkova EA et al. Rezul'taty eksperimental'nykh issledovaniĭ na telyatakh pervogo otechestvennogo implantiruemogo osevogo nasosa. Vestnik transplantologii i iskusstvennykh organov = Russian Journal of Transplantology and Artifi cial Organs. 2013; 3: 49–58.; Готье СВ, Иткин ГП, Шемакин СЮ, Саитгареев РШ, Попцов ВН, Захаревич ВМ и др. Первый опыт клинического применения отечественного аппарата вспомогательного кровообращения на базе имплантируемого осевого насоса для двухэтапной трансплантации сердца. Вестник трансплантологии и искусственных органов. 2013; 3: 92–101. Gautier SV, Itkin GP, Shemakin SYu, Saitgareev RSh, Poptsov VN, Zakharevich VM et al. Pervyĭ opyt klinicheskogo primeneniya otechestvennogo apparata vspomogatel'nogo krovoobrashcheniya na baze implantiruemogo osevogo nasosa dlya dvukhetapnoĭ transplantatsii serdtsa. Vestnik transplantologii i iskusstvennykh organov = Russian Journal of Transplantology and Artifi cial Organs. 2013; 3: 92–101.; https://journal.transpl.ru/vtio/article/view/450
-
12Academic Journal
Authors: Герке, В.
Subject Terms: ТРОМБОЭМБОЛИЯ, ЭМБОЛ, ГЕМОКОАГУЛЯЦИЯ, ЗАСТОЙНАЯ СЕРДЕЧНАЯ НЕДОСТАТОЧНОСТЬ, ТРОМБООБРАЗОВАНИЕ, АНТИКОАГУЛЯНТЫ, КЛОПИДОГРЕЛЬ, ВАРФАРИН, ТРОМБОЗ, АНТИАГРЕГАНТЫ, ТРОМБОЦИТЫ, АСПИРИН
File Description: text/html
-
13Academic Journal
Authors: Жданова, Т., Садыкова, Ю., Корелина, A., Назаров, A.
Subject Terms: ТРАНСПЛАНТАЦИЯ ПОЧКИ, АРИТМИИ, ЗАСТОЙНАЯ СЕРДЕЧНАЯ НЕДОСТАТОЧНОСТЬ
File Description: text/html
-
14Academic Journal
Authors: Репина, М., Кузьмина-крутецкая, С.
Subject Terms: ПРИОБРЕТЕННЫЕ ПОРОКИ СЕРДЦА, ЗАСТОЙНАЯ СЕРДЕЧНАЯ НЕДОСТАТОЧНОСТЬ, БЕРЕМЕННОСТЬ
File Description: text/html
-
15Academic Journal
Authors: Бокерия, Л., Базаев, В., Филатов, А., Бокерия, О., Меликулов, А., Висков, Р., Грицай, А., Амиркулов, Б., Кислицина, О.
Subject Terms: ЗАСТОЙНАЯ СЕРДЕЧНАЯ НЕДОСТАТОЧНОСТЬ, ХРОНИЧЕСКАЯ ФИБРИЛЛЯЦИЯ ПРЕДСЕРДИЙ, БИВЕНТРИКУЛЯРНАЯ СТИМУЛЯЦИЯ
File Description: text/html
-
16Academic Journal
Source: Экспериментальная и клиническая гастроэнтерология.
Subject Terms: 03 medical and health sciences, 0302 clinical medicine, ВРОЖДЕННЫЙ ПОРОК СЕРДЦА,ЛЕГОЧНАЯ ГИПЕРТЕНЗИЯ,ЗАСТОЙНАЯ СЕРДЕЧНАЯ НЕДОСТАТОЧНОСТЬ,ОТКРЫТОЕ ОВАЛЬНОЕ ОКНО,АНОМАЛЬНОЕ ВПАДЕНИЕ ЛЕГОЧНЫХ ВЕН,ЦИРРОЗ ПЕЧЕНИ,CONGENITAL HEART DISEASE,PULMONARY HYPERTENSION,CONGESTIVE HEART DISEASE,PATENT FORAMEN OVALE,ANOMALOUS PULMONARY VENOUS CONNECTION,LIVER CIRRHOSIS, 3. Good health
File Description: text/html
-
17Academic Journal
Source: Вестник Казахского Национального медицинского университета.
Subject Terms: артериальная гипертензия, сахарный диабет 2-го типа, коронарная болезнь сердца, застойная сердечная недостаточность, ампутации нижних конечностей, 3. Good health
File Description: text/html
-
18Academic Journal
Source: Research'n Practical Medicine Journal.
Subject Terms: рак молочной железы, качество жизни, антрациклины, трастузумаб, застойная сердечная недостаточность, 3. Good health
File Description: text/html
-
19Academic Journal
Authors: Репина, М., Кузьмина-крутецкая, С.
Subject Terms: БЕРЕМЕННОСТЬ, ЗАБОЛЕВАНИЯ СЕРДЦА, ЗАСТОЙНАЯ СЕРДЕЧНАЯ НЕДОСТАТОЧНОСТЬ
File Description: text/html
-
20Academic Journal
Source: VetPharma.
Subject Terms: ТРОМБОЭМБОЛИЯ, ЭМБОЛ, ГЕМОКОАГУЛЯЦИЯ, ЗАСТОЙНАЯ СЕРДЕЧНАЯ НЕДОСТАТОЧНОСТЬ, ТРОМБООБРАЗОВАНИЕ, АНТИКОАГУЛЯНТЫ, КЛОПИДОГРЕЛЬ, ВАРФАРИН, ТРОМБОЗ, АНТИАГРЕГАНТЫ, ТРОМБОЦИТЫ, АСПИРИН, 3. Good health
File Description: text/html
